Is Proxalutamide a Game Changing COVID-19 Therapy or More BioPharma Marketing?

Recently the Chinese online media Global Times reported on an exclusive interview with Kintor Pharmaceutical Limited (Kintor Pharma) Chief Financial Officer Lucy Lu.  Based on what is deemed “unbelievably high efficacy” associated with interim Phase 3 clinical trial results of the study investigating proxalutamide, the CFO shared more information about this and other studies ongoing. Interim study results will be available in December. TrialSite provides a brief breakdown of proxalutamide, the studies and the sponsor. Does this investigational product show material promise as a treatment for COVID-19?

The Investigational Product

Back in July of 2021 TrialSite reported that Kintor Pharma received an emergency use authorization (EUA) for Proxalutamide in the treatment of COVID-19 in the South American nation of Paraguay.  The action seems rushed based on paltry data associated with a study involving 25 patients.

Developed in house by Kintor Pharma, Proxalutamide is a selective high-affinity silent antagonist of the androgen receptor (AR) previously used in clinical research to treat prostate and breast cancer. While approved on an EUA basi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee